Report topline data from the Phase 1 healthy volunteer trial of SION-451
Delivered by the deadline
Under re-examination This entry has been challenged and is being re-checked against the sources.
- Announced
- 11 Aug 2025
- Due
- 30 Jun 2026
- Delivered
- June 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Topline data are anticipated in mid-2026”
What we found
Evidence strength A What the grades mean
The company reported positive topline data from the Phase 1 healthy volunteer trial of SION-451 in June 2025, which occurred before the mid-2026 deadline.
-
A Sionna Therapeutics, Inc. 10-Q filed 2026-05-12
“In June 2025, we announced positive topline data from our two randomized, double-blinded, placebo-controlled Phase 1 clinical trials evaluating SION-719 and SION-451, our lead NBD1 stabilizer product candidates, in healthy volunteers” ✓ confirmed on the page
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +84 days
- 3 versions
-
Version 1 · original · stated 11 Aug 2025
Deadline 30 Jun 2026 (“mid-2026”) · wording expected
-
Version 2 · stated 12 May 2026
Deadline 30 Sep 2026 (“summer of 2026”)
“Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026”
-
Version 3 · stated 6 Aug 2026
Deadline 22 Sep 2026 (“summer of 2026”)
“Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 also is on track for topline data summer of 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Topline data from SION-451 Phase 1 trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and reads it as “no_evidence”.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Sionna Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-SION-001963 · Corrections policy